-continued

```
 1               5

<210> SEQ ID NO 572
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 572

Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr
 1               5                  10                  15

Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys
            20                  25                  30


<210> SEQ ID NO 573
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 573

Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr
 1               5                  10                  15

Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Phe Cys
            20                  25                  30


<210> SEQ ID NO 574
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 574

Gln Val Trp Asp Ser Ser Ser Asp Pro Val Val
 1               5                  10


<210> SEQ ID NO 575
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 575

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
 1               5                  10
```

What is claimed is:

1. An isolated monoclonal antibody, wherein, when bound to PCSK9, the monoclonal antibody binds to at least one of the following residues: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO:3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.

2. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least S153.

3. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least I154.

4. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least P155.

5. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least T377.

6. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least R194.

7. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least D238.

8. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least A239.

9. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least I369.

10. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least S372.

11. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least D374.

12. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least C375.

13. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least C378.

14. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least F379.

15. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least V380.

16. The isolated monoclonal antibody of claim **1**, wherein the monoclonal antibody binds to at least S381.

17. A pharmaceutical composition comprising an isolated monoclonal antibody, wherein, when bound to PCSK9, the isolated monoclonal antibody binds to at least one of the following residues: S153, I154, P155, R194, D238, A239,